echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Urinary System > First-line treatment for bladder cancer, with a combined ADC/Keytruda response rate of 64.5% ESMO

    First-line treatment for bladder cancer, with a combined ADC/Keytruda response rate of 64.5% ESMO

    • Last Update: 2022-09-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    ▎ WuXi AppTec content team editor

    Astellas Pharma and Seagen today announced the latest trial results




    Urothelial carcinoma is the most common type of bladder cancer, accounting for about 90% of all bladder cancers, and can also occur in the renal pelvis, ureters, and urethra



    Padcev is an antibody-conjugated drug


    The EV-103 trial is a ongoing multi-cohort, open-label, multicenter Phase 1b/2 trial



    Data analysis showed that the confirmed objective response rate in the Padcev and Keytruda combination groups was 64.



    The security aspect is consistent



    According to the published summary, these new data support the continuation of trials to test the possibility



    References:[1] Annals of Oncology (2022) 33 (suppl_7): S808-S869.



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.